ALAnnalyse Lalljie

Annalyse Lalljie

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Annalyse Lalljie has a total of 7 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Assessment of BioFire Gastrointestinal Panel unconfirmed positive results for enteropathogenic bacteria and Norovirus and accuracy of a post-analytical algorithm to mitigate unconfirmed results

    by Annalyse Lalljie, Indre Budvytiene, Niaz Banaei

    This study investigated unconfirmed-positive rates with the BioFire FilmArray Gastrointestinal Panel (FAGP) for bacterial targets and Norovirus and determined if melt curve analysis can mitigate unconfirmed results. Positive FAGP results for bacteria were classified as culture-positive or culture-negative and as melt curve-specific or curve-nonspecific. Culture-negative samples were prospectively confirmed with the Xpert GI PCR Panel. Norovirus-positive results were classified as melt curve-specific or curve-nonspecific and confirmed with the Xpert Norovirus PCR. The primary aim was to measure the accuracy of FAGP with and without melt curve analysis. Culture-negative rate was 24.6% (100/407) for Campylobacter jejuni , 90.1% (100/111) for Campylobacter 2 targeting Campylobacter coli and Campylobacter helveticus/upsaliensis , 58.1% (100/172) for Shigella /enteroinvasive Escherichia coli (EIEC), and 38.5% (100/260) for Salmonella spp. Positive predictive value (PPV) of FAGP based on culture and Xpert GI PCR Panel was 100% (42/42) for C. jejuni , 16.7% (4/24) for Campylobacter 2, 94.1% (16/17) for Shigella /EIEC, and 73.2% (30/41) for Salmonella spp. Inclusion of melt curve analysis had no impact on the sensitivity but significantly improved the specificity for Campylobacter spp. from 75% (60/80) to 100% (80/80; P < 0.001), Shigella /EIEC from 98.0% (49/50) to 100% (50/50; P > 0.05), and for Salmonella spp. from 78.0% (39/50) to 96% (48/50; P < 0.01). PPV for Norovirus was 7.6% (7/92) for Norovirus 1 and 76.0% (73/96) for Norovirus 2. Melt curve analysis improved accuracy for Norovirus 2 (sensitivity 100% [73/73] to 98.6% [72/73; P > 0.05]; specificity 79.8% [91/114] to 98.2% [112/114; P < 0.001]) but not for Norovirus 1 (sensitivity 100% [7/7] to 28.6% [2/7; P < 0.01]; specificity 52.0% [92/177] to 100% [177/177; P < 0.001]). FAGP has a high unconfirmed-positive rate for Campylobacter spp., Shigella /EIEC, and Salmonella spp. and Norovirus, which can be partially mitigated with melt curve analysis. IMPORTANCE: The BioFire FilmArray Gastrointestinal Panel is a widely used syndromic panel for rapid diagnosis of gastroenteritis, but recent studies have shown an alarming rate of false-positive results for Norovirus, and concerns have been raised for Campylobacter spp. and other bacterial targets. This study found substantial rates of unconfirmed positive results with the FilmArray Gastrointestinal Panel for Campylobacter spp., Shigella /enteroinvasive Escherichia coli (EIEC), and Salmonella spp. in addition to Norovirus. Through defining specific melt curve parameters, this study shows that it is possible to mitigate unconfirmed positives and assure the quality of results fully for Campylobacter spp., Shigella /EIEC, and Salmonella spp. and partially for Norovirus.

  • Open Access

    Accuracy of plasma cell-free DNA PCR versus mNGS for non-invasive diagnosis of invasive mold disease

    by Karolina Pusz-Bochenska, Kanagavel Murugesan, Fiona Senchyna, Annalyse Lalljie, Indre Budvytiene, Niaz Banaei

    Cell-free DNA (cfDNA) detection in plasma is a novel testing modality for non-invasive diagnosis of invasive mold disease (IMD) in immunocompromised patients. The accuracy of PCR compared to metagenomic next-generation sequencing (mNGS) for diagnosis of IMD remains unknown. Plasma samples from patients with proven and probable IMD and no IMD were tested with mold PCR and shotgun mNGS. Mold PCR detected Aspergillus species, Mucorales agents, Fusarium species, Scedosporium species, and Lomentospora prolificans . The sensitivity and specificity of mold PCR and mNGS were measured. Ninety-four patients with proven (48) and probable (48) IMD due to Aspergillus species (64), Mucorales agents (13), Scedosporium species and Lomentospora prolificans (13), and Fusarium species (6), and 62 patients with no IMD were included in this study. 99.4% (155) of the patients were immunosuppressed. The overall sensitivity and specificity were 62.5% (60/96; 95% CI 52.0–72.2) and 99.8% (535/536; 95% CI 99.0–100), respectively, for mold PCR and 43.8% (42/96; 95% CI 33.6–54.3; P < 0.001) and 99.6% (534/536; 95% CI 98.7–100; P = 1.0), respectively, for mNGS. The proportion of mold PCR-positive mNGS-negative results was 16.0% (4/25) in focal cases compared with 25.0% (11/44; P = 0.384) and 18.5% (5/27; P = 0.810) in multifocal and disseminated cases, respectively. The median PCR cycle threshold was 40.6 (IQR, 37.5–41.5) in PCR-positive mNGS-negative cases compared with 37.3 (IQR, 34.5–39.3; P = 0.004) in PCR-positive mNGS-positive cases. Plasma cfDNA PCR is more sensitive than mNGS for the diagnosis of IMD in immunocompromised patients. Lower sensitivity of mNGS was associated with lower mold cfDNA burden. IMPORTANCE: Invasive mold disease (IMD) is a major cause of morbidity and mortality in immunocompromised patients. Early diagnosis and initiation of tailored antifungal therapy are critical for optimizing outcomes in patients with IMD. Detection of circulating fungal cell-free DNA (cfDNA) in the acellular fraction of blood is a novel testing modality that is increasingly used for early and non-invasive diagnosis of IMD. This study represents the first head-to-head accuracy study to compare the sensitivity and specificity of PCR with mNGS for the diagnosis of IMD. The study showed that the overall mold PCR was significantly more sensitive compared with mNGS, while both assays demonstrated very high specificity. Similar trends were observed in a smaller subgroup of patients with invasive aspergillosis, mucormycosis, and scedosporiosis. The findings have implications for assay selection when seeking to non-invasively diagnose IMD in immunocompromised patients.

  • Accuracy of Plasma Cell-Free DNA Polymerase Chain Reaction for Diagnosis of Coccidioidomycosis

    by Annalyse Lalljie, Indre Budvytiene, Joseph L Wheat, Elitza S Theel, Niaz Banaei

    Background: Coccidioidomycosis is the most prevalent endemic mycosis in the United States. Diagnosis of coccidioidomycosis can be challenging due to limitations of conventional diagnostics. Detection of fungal plasma cell-free DNA (cfDNA) is a novel noninvasive testing modality for the diagnosis of invasive fungal disease. In this study, we characterized the performance of Coccidioides plasma cfDNA polymerase chain reaction (PCR). Methods: A retrospective study was conducted in patients with suspected coccidioidomycosis who underwent plasma cfDNA PCR testing and conventional fungal testing for Coccidioides immitis and Coccidioides posadasii. Patients were categorized per the EORTC/MSGERC case definitions as proven or probable for sensitivity analyses and no coccidioidomycosis for specificity analyses. Results: Overall, 362 plasma samples from unique patients were included in this study. The overall sensitivity, specificity, and positive- and negative-predictive values of Coccidioides plasma cfDNA PCR at 0.04% prevalence were 57.5% (27/47; 95% CI, 42.2%–71.7%), 100% (315/315; 95% CI, 98.8%–100%), 100% (95% CI, 87.2%–100%), and 100% (95% CI, 100%–100%), respectively. The sensitivity was 33.3% (2/6; 95% CI, 4.3%–77.7%) in patients with pulmonary focal disease, 66.7% (14/21; 95% CI, 43.0%–85.4%; P≥.05) in patients with pulmonary multifocal disease, and 52.6% (10/19; 95% CI, 39.6%–77.9%; P≥.05) in patients with disseminated coccidioidomycosis. In patients with concurrent antigen results, the sensitivity of cfDNA PCR was 58.3% (14/24; 95% CI, 39.6%–77.9%) compared with 37.5% (9/24; 95% CI, 18.8%–59.4%; P≥.05) for antigen. Conclusions: Coccidioides plasma cfDNA PCR is modestly sensitive but highly specific, which can be useful for rapid and noninvasive diagnosis of coccidioidomycosis.